MondegarAI
Euclidean Capital LLC

Q2 2024 · 13F-HR

Euclidean Capital LLCholdings as filed

Filed 2024-08-14 · accession 0001012975-24-000328

$795.8M
Reported value
11
Positions
2024-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
78462F103SPYSPDR S&P 500 ETF TR$624.2M78.4%1,146,979CommonSOLE
46429B598INDAISHARES TR$135.3M17.0%2,425,144CommonSOLE
344174107FHTXFOGHORN THERAPEUTICS INC$9.0M1.14%1,573,761CommonSOLE
68622P109ORICORIC PHARMACEUTICALS INC$7.0M0.88%989,410CommonSOLE
014442107ALECALECTOR INC$5.9M0.75%1,307,858CommonSOLE
69353Y103PMVPPMV PHARMACEUTICALS INC$4.3M0.53%2,627,643CommonSOLE
90138Q10823ANDME HOLDING CO$4.0M0.50%10,243,122CommonSOLE
87990A106TNYATENAYA THERAPEUTICS INC$3.1M0.40%1,015,705CommonSOLE
75382E109RAPT THERAPEUTICS INC$2.0M0.25%657,899CommonSOLE
86889P208SRZNSURROZEN INC$960,2710.12%87,696CommonSOLE
86889P117SRZNWSURROZEN INC$2,8360.00%170,833CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.